Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Up 5.54%
As of Tuesday, October 20, C4 Therapeutics, Inc.’s CCCC share price has surged by 5.54%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Up 5.42%
As of Monday, October 19, C4 Therapeutics, Inc.’s CCCC share price has surged by 5.42%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Down 6.37%
As of Tuesday, October 13, C4 Therapeutics, Inc.’s CCCC share price has dipped by 6.37%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Up 6.84%
As of Friday, October 09, C4 Therapeutics, Inc.’s CCCC share price has surged by 6.84%, which has investors questioning if this is right time to sell.Jenna Brashear
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Up 5.59%
As of Wednesday, September 30, C4 Therapeutics, Inc.’s CCCC share price has surged by 5.59%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $389.4 | $228.4 | 35% |
|
| Shares Out (Mil) | 130.7 | 53.9 | 68% |
|
| Institutional Ownership | 98.8% | 92.9% | 82% |
|
| Float (Mil) | 94.5 | 41.7 | 59% |
|
| Beta | 2.95 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 2,844 | 582 | 86% |
|
| Price Change (52-week) |
33.5% | 47.6% | 77% |
|
| Growth | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 1.6% | 13.6% | 23% |
|
| Net Income (5yr) | (9.6%) | (10.1%) | 30% |
|
| EPS (5yr) | 26.3% | 15.8% | 77 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (50.9%) | (15.7%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.212) | ($0.856) | ($0.962) | |
| Month Ago EPS | ($0.223) | ($0.885) | ($0.998) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.253) | ($0.956) | ($1.040) | |
| Year/Year Chg | 17.1% | (32.4%) | (8.8%) | |
| Financials | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($101) | ($44) | 11% |
|
| EPS (TTM) | ($0.908) | ($1.500) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($85) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 44% |
|
| Long-Term Debt (Q1) (Mil) | $50 | $4 | 39% |
|
| Enterprise Value (Q1) (Mil) | $174 | $177 | 25% |
|
| Valuation | CCCC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.57 | 2.19 | 44% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.3% | 66.9% | 92% |
|
| Net Margin | (289.4%) | (73.7%) | 3% |
|
| ROA | (30.9%) | (47.1%) | 16% |
|
| ROE | (48.1%) | (54.1%) | 16% |
|
| Liabilities to Assets | 31.2% | 29.1% | 22% |
|
| F-Score | 5 | 2 | 50% |
|
Passing Stock Screens
As of 10/20/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.3% |
| +/- S&P 500: | +13.8 |
